Aurora Cannabis (ACB) Expands Global Footprint With New Europe and Australia Deals

Company Overview - Aurora Cannabis Inc. (NASDAQ:ACB) is recognized as one of the top sin stocks to consider for investment in 2026, with notable market growth in Europe and Australia [1] - The company operates in the cannabis industry, producing, distributing, and selling cannabis and cannabis-derived products, targeting both medical and consumer segments [4] Recent Developments - On December 2, Aurora's subsidiary, MedReleaf Australia, entered into a distribution agreement with Leafio, Montu Australia's wholesale arm, aimed at providing training materials for medical professionals and enhancing patient access to medical cannabis products across Australia [2] - Following this, on December 11, Aurora launched a new high-potency cannabis product named Black Jelly in the Polish medicinal market, which contains 27% THC and less than 1% CBD [3] - Black Jelly is produced in Aurora's Canadian facilities that are certified under GACP and EU-GMP standards, and it is now available to Polish prescribers [4] Product Portfolio - Aurora's medical cannabis portfolio includes several brands such as MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed, which will be marketed by Leafio [2] - The introduction of Black Jelly adds to the Cannabis flos Aurora range, which already includes products like Farm Gas and Sourdough [3]